Inicio>>Signaling Pathways>> Metabolism>> Glucokinase>>PF-04937319

PF-04937319

Catalog No.GC36881

PF-04937319 es un activador de la glucoquinasa (GKA) con un valor de EC50 de 154,4 μM, una de las estrategias mÁs prometedoras para el tratamiento de la diabetes mellitus tipo 2.

Products are for research use only. Not for human use. We do not sell to patients.

PF-04937319 Chemical Structure

Cas No.: 1245603-92-2

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO)
109,00 $
Disponible
1mg
40,00 $
Disponible
5mg
99,00 $
Disponible
10mg
171,00 $
Disponible
25mg
351,00 $
Disponible
50mg
639,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

PF-04937319 is a glucokinase activator (GKA) with EC50 value of 154.4 μM, one of the most promising strategies for the treatment of type 2 diabetes mellitus[1].PF-04937319 is designed to maintain glucose-lowering efficacy while mitigating the risk of hypoglycaemia observed with many other GKAs[2]. EC50: 154.4 μM (GSA) (PF-04937319)[1]

[1]. Dzyurkevich MS, et al. Pyridoxine dipharmacophore derivatives as potent glucokinase activators for the treatment of type 2 diabetes mellitus. Sci Rep. 2017 Nov 22;7(1):16072. [2]. Amin NB, et al. Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes. Diabetes Obes Metab. 2015 Aug;17(8):751-9.

Reseñas

Review for PF-04937319

Average Rating: 5 ★★★★★ (Based on Reviews and 40 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PF-04937319

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.